Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia Academic Article uri icon

Overview

MeSH Major

  • Arabinonucleosides
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma

abstract

  • Clofarabine is active as a single agent in pediatric patients with multiple relapsed or refractory ALL. The toxicity profile is as expected in this heavily pretreated patient population. Studies exploring rational combinations of clofarabine with other agents are ongoing in an effort to maximize clinical benefit.

publication date

  • April 20, 2006

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1200/JCO.2005.03.8554

PubMed ID

  • 16622268

Additional Document Info

start page

  • 1917

end page

  • 23

volume

  • 24

number

  • 12